Biotech Values

[DewDiligence]

ABT—SVR36 [i.e. % of patients with undetectable virus 36 weeks post-treatment] in the PILOT study is down to 82% from SVR24 that was 91%.

On first glance, this looks ominous; however, SVR36 data have rarely been reported, so it’s not yet clear how this revelation should be benchmarked.